Overview

Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to evaluate the safety and effectiveness of the drugs lenalidomide and ofatumumab in the treatment of chronic lymphocytic leukemia (CLL).
Phase:
Phase 2
Details
Lead Sponsor:
Medical University of South Carolina
Collaborators:
Celgene Corporation
GlaxoSmithKline
Treatments:
Antibodies, Monoclonal
Lenalidomide
Ofatumumab
Rituximab
Thalidomide